A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure

NARecruitingINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2026

Conditions
Hemodialysis ComplicationHeart Failure
Interventions
DRUG

Vericiguat

Under the premise of ensuring safety, treat with a stable dose of Vericiguat 2.5mg PO QD for 2 weeks. After 2 weeks, increase the dose to 5mg PO QD. If blood pressure elevation occurs during the operation phase, the researchers suggest titrating or starting additional antihypertensive drugs, with a follow-up of 12 months. If the patient has tolerability issues (symptomatic hypotension or SBP\<90 mmHg), the dose should be reduced or discontinued.

Trial Locations (1)

510000

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors
lead

Guangdong Provincial People's Hospital

OTHER

NCT07047547 - A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure | Biotech Hunter | Biotech Hunter